RxDoctor Payments Data

Stacie Schaible, PA

Family Medicine · Gilbert, AZNPI 1316968548

Payments from drug & device makers

$2,636in general payments, 2019–2025

Across 155 payments — averaging $17.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$704
  • Pfizer$286
  • Lilly USA, LLC$203
  • AstraZeneca$195
  • Astellas Pharma US Inc$145
  • Boehringer Ingelheim$110
  • plus $994 from 27 others

What the payments were for

  • Food & beverage$2,61899%
  • Entertainment$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,636 in reported general payments places this provider in the 80th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$111,217
Medicare patients
316
Services billed
1,284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$72,135
TrulicityDulaglutide41$69,782
JardianceEmpagliflozin50$57,371
FarxigaDapagliflozin Propanediol51$47,272
ProliaDenosumab24$41,323
JanuviaSitagliptin Phosphate38$36,844
MounjaroTirzepatide28$34,165
EliquisApixaban28$29,762
RybelsusSemaglutide11$24,373
TradjentaLinagliptin24$22,167
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$18,831
VraylarCariprazine Hcl12$17,624
MyrbetriqMirabegron17$16,431
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$14,401
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$13,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$203$103,94669 claims
Novo NordiskOzempic, Rybelsus$16$96,50857 claims
Boehringer IngelheimJardiance, Tradjenta$110$79,53874 claims
AstraZenecaFarxiga, Breztri Aerosphere$195$61,03566 claims
AmgenProlia$30$41,32324 claims
MerckJanuvia$96$36,84438 claims
PfizerEliquis, Paxlovid$286$31,11341 claims
GSKTrelegy Ellipta, Anoro Ellipta$105$28,83831 claims
AbbVieVraylar, Synthroid$704$20,53662 claims
Astellas Pharma US IncMyrbetriq$145$16,43117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Gilbert

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →